Liraglutide

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

Also Known As:

Networked: 2559 relevant articles (534 outcomes, 925 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Buse, John B: 38 articles (01/2022 - 07/2009)
2.	Madsbad, Sten: 31 articles (01/2022 - 06/2004)
3.	Nauck, Michael A: 29 articles (01/2022 - 06/2005)
4.	Vilsbøll, Tina: 28 articles (01/2022 - 02/2007)
5.	Zinman, Bernard: 27 articles (01/2022 - 07/2009)
6.	Hunt, Barnaby: 24 articles (01/2022 - 04/2013)
7.	Bain, Stephen C: 23 articles (01/2022 - 07/2007)
8.	Rasmussen, Søren: 21 articles (01/2022 - 01/2017)
9.	Pratley, Richard E: 21 articles (08/2021 - 04/2010)
10.	Sesti, Giorgio: 21 articles (09/2020 - 07/2009)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 08/01/2016 - "In patients with type 2 diabetes, 6months liraglutide treatment was associated with a significant improvement in diastolic function." 03/01/2022 - "Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study." 01/01/2022 - "Liraglutide is an effective treatment for the management of type 2 diabetes mellitus (T2DM). " 02/01/2009 - "Liraglutide: a new treatment for type 2 diabetes." 01/01/2019 - "Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting."
2.	Weight Loss (Weight Reduction) 12/01/2009 - "Throughout the trials, liraglutide was associated with weight reduction; in most instances, the reduction from baseline was significantly greater than that seen with comparators. " 03/01/2017 - "Liraglutide resulted in weight loss in most participants (-3.12±1.72 kg, P=0.007) and significant reduction in visceral AT (VAT). " 10/01/2019 - "Both treatment cohorts had similar patterns of A1C change, and liraglutide had significantly greater weight loss, which are similar to findings from clinical trials." 11/01/2023 - "Treatment with liraglutide for 6 months promoted weight loss, improved cardiometabolic and inflammatory parameters and led to a significant reduction in FMT correlated with AC in obese MetS patients of both sexes." 04/01/2023 - "Percent weight loss was significantly greater in the liraglutide versus the placebo group (5.2 ± 1.0% vs. 0.9 ± 0.7%, p = 0.005). "
3.	Body Weight (Weight, Body) 09/01/2015 - "As appetite suppressions and associated decreases in body weights were not observed in obese patients, the efficacy of liraglutide at 0.9 mg did not appear to be high. " 06/01/2015 - "Based on this population pharmacokinetic analysis, the liraglutide dose regimen that was found to be clinically effective in adults is predicted to achieve the same range of exposure in the pediatric population (10-17 years of age) with a pre-trial body weight range of 57-214 kg." 07/02/2015 - "In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control. " 01/01/2018 - "In this observational study conducted in routine clinical practice for up to 2 years, treatment with liraglutide improved HbA1c and reduced body weight in a similar fashion to that observed under randomized clinical trial conditions. " 07/01/2016 - "This could possibly lead to compensatory changes in energy homeostasis that could over time limit the efficacy of liraglutide to decrease body weight. "
4.	Obesity 01/28/2023 - "deltoidea was considered the most effective in mitigating diet-induced obesity, with positive effects sometimes exceeding those of the reference drug liraglutide. " 07/03/2018 - "Thus, liraglutide could be an effective treatment of the most common form of monogenic obesity." 12/21/2021 - "However, high-dose liraglutide-liraglutide 3 mg daily, has been demonstrated to be a safe and effective treatment for obesity, with or without DM. " 03/01/2022 - "In S-LITE, liraglutide (with or without exercise) was effective in reducing weight regain in subjects with obesity. " 12/02/2023 - "Liraglutide 3mg is effective and safe among patients with HS and obesity. "
5.	Insulin Resistance 05/01/2013 - "Our study also showed potent inhibitory effects of liraglutide on MKK4/JNK signalling which may be a mechanism for the observed improved insulin sensitivity and inflammatory stress induced by HFD and hypoadiponectinaemia." 01/01/2021 - "OMM quantified, both in SAR425899 and liraglutide, a significant improvement in insulin sensitivity (203% [58%, 440%] and 36% [21%, 197%]), basal beta-cell responsiveness (67% [34%, 112%] and 40% [16%, 59%]), and above-basal beta-cell responsiveness (139% [64%, 261%] and 69% [-15%, 120%]). " 06/01/2022 - "Insulin resistance might be improved with the use of liraglutide. " 10/01/2013 - "Our results suggest that liraglutide ameliorates glycometabolism and insulin resistance in diabetic KKAy mice by stimulating insulin secretion, increasing glycogenesis and glycolysis and upregulating the expression of GLUT4." 10/01/2013 - "Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice."

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Glucagon-Like Peptide 1 (GLP 1)
3.	Glucose (Dextrose)
4.	Exenatide (Byetta)
5.	Glucagon-Like Peptide-1 Receptor
6.	Metformin (Glucophage)
7.	semaglutide
8.	Glucagon-Like Peptide-1 Receptor Agonists
9.	Lipids
10.	Hypoglycemic Agents (Hypoglycemics)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Injections
4.	Bariatric Surgery
5.	Aftercare (After-Treatment)